Prince Pharmaceutical Co., Ltd. (6935) Stock Statistics & Valuation Metrics
Total Valuation
Prince Pharmaceutical Co., Ltd. has a market cap or net worth of TWD 1.27B. The enterprise value is ―.
- Market Cap
- TWD 1.27B
- Enterprise Value
- ―
Share Statistics
Prince Pharmaceutical Co., Ltd. has 47,410,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 47,410,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Prince Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 8.08%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 8.08%
- Return on Capital Employed (ROCE)
- 0.09
- Revenue Per Employee
- 4.89M
- Profits Per Employee
- 445.93K
- Employee Count
- 216
- Asset Turnover
- 0.70
- Inventory Turnover
- 4.06
Valuation Ratios
The current PE Ratio of Prince Pharmaceutical Co., Ltd. is 7.61. Prince Pharmaceutical Co., Ltd.’s PEG ratio is 0.01.
- PE Ratio
- 7.61
- PS Ratio
- 0.82
- PB Ratio
- 1.15
- Price to FCF
- 5.94
- Price to Operating Cash Flow
- 5.21
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Prince Pharmaceutical Co., Ltd. had revenue of 1.06B and earned 96.32M in profits. Earnings per share was 2.63.
- Revenue
- 1.06B
- Gross Profit
- 222.55M
- Operating Income
- 110.88M
- Pretax Income
- 104.74M
- Net Income
- 96.32M
- EBITDA
- 175.94M
- Earnings Per Share (EPS)
- 2.63
Cash Flow
In the last 12 months, operating cash flow was 192.76M and capital expenditures -23.63M, giving a free cash flow of 169.14M billion.
- Operating Cash Flow
- 192.76M
- Free Cash Flow
- 169.14M
- Free Cash Flow per Share
- 4.52
Dividends & Yields
Prince Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.83%
- Dividend Per Share
- ―
- Dividend Yield
- 1.83%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 16.84%
- Earnings Yield
- 12.95%
Stock Price Statistics
- Beta
- 0.23
- 52-Week Price Change
- -12.83%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 37.01
- Average Volume (3m)
- 15.78K
Financial Position
Prince Pharmaceutical Co., Ltd. as a current ratio of 1.81, with Debt / Equity ratio of 50.32%
- Current Ratio
- 1.81
- Quick Ratio
- 1.15
- Debt to Market Cap
- 0.26
- Net Debt to EBITDA
- 1.53
- Interest Coverage Ratio
- 11.57
Taxes
In the past 12 months, Prince Pharmaceutical Co., Ltd. has paid 8.42M in taxes.
- Income Tax
- 8.42M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Prince Pharmaceutical Co., Ltd. EV to EBITDA ratio is 5.51, with an EV/FCF ratio of 7.02.
- EV to Sales
- 0.97
- EV to EBITDA
- 5.51
- EV to Free Cash Flow
- 7.02
- EV to Operating Cash Flow
- 6.16
Balance Sheet
Prince Pharmaceutical Co., Ltd. has TWD 224.85M in cash and marketable securities with TWD 408.28M in debt, giving a net cash position of -TWD 183.43M billion.
- Cash & Marketable Securities
- TWD 224.85M
- Total Debt
- TWD 408.28M
- Net Cash
- -TWD 183.43M
- Net Cash Per Share
- -TWD 3.87
- Tangible Book Value Per Share
- TWD 23.29
Margins
Gross margin is 21.39%, with operating margin of 12.37%, and net profit margin of 10.62%.
- Gross Margin
- 21.39%
- Operating Margin
- 12.37%
- Pretax Margin
- 12.00%
- Net Profit Margin
- 10.62%
- EBITDA Margin
- 17.61%
- EBIT Margin
- 12.65%
Analyst Forecast
The average price target for Prince Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 53.43%
- EPS Growth Forecast
- ―
